Cargando…
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
Mesothelin (MSLN) is a glycophosphatidylinositol (GPI)-linked cell surface protein highly expressed in several types of malignant tumors sometimes in association with increased tumor aggressiveness and poor clinical outcome. In the present study, 1562 tumors were immunohistochemically analyzed for m...
Autores principales: | Inaguma, Shingo, Wang, Zengfeng, Lasota, Jerzy, Onda, Masanori, Czapiewski, Piotr, Langfort, Renata, Rys, Janusz, Szpor, Joanna, Waloszczyk, Piotr, Okoń, Krzysztof, Biernat, Wojciech, Ikeda, Hiroshi, Schrump, David S., Hassan, Raffit, Pastan, Ira, Miettinen, Markku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432294/ https://www.ncbi.nlm.nih.gov/pubmed/28460459 http://dx.doi.org/10.18632/oncotarget.15814 |
Ejemplares similares
-
CD70 and PD‐L1 (CD274) co‐expression predicts poor clinical outcomes in patients with pleural mesothelioma
por: Inaguma, Shingo, et al.
Publicado: (2023) -
Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013) -
MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2014) -
New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
por: Zhang, Yi-Fan, et al.
Publicado: (2015) -
Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2017)